Rinvoq — Medical Mutual

Initial criteria

• Patient age ≥ 2 years
• Patient had a 3-month trial of ≥1 TNF inhibitor OR unable to tolerate 3-month trial
• Rinvoq prescribed by or in consultation with a rheumatologist or dermatologist

Reauthorization criteria

• Patient established on therapy ≥ 6 months
• Patient experienced beneficial response by ≥ 1 objective measure OR improvement in at least 1 symptom (e.g., less joint pain, morning stiffness, fatigue, improved function, less swelling)

Approval duration

initial 6 months; renewal 1 year